Merrill keeps Nektar at buy

Nektar Therapeutics Inc. was kept at a buy by Merrill Lynch analyst Hari Sambasivam. Merrill's estimates for the quarter include total revenues of $32.7 million and pro forma net loss of $32.7 million, or $0.37 per share. Consensus loss per share for the quarter is $0.39. Key milestones in 2006 include details of Exubera pricing, marketing and pre-launch activities and progress on reimbursement. Shares of the San Carlos, Calif., biopharmaceutical company were up 6 cents, or 0.28%, at $21.57 on volume of 1,903,728 shares versus the three-month running average of 1,574,670 shares. (Nasdaq: NKTR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.